Cover Image
Market Research Report

Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 363568
Published Content info 64 Pages
Delivery time: 1-2 business days
Price
Back to Top
Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H2 2019
Published: November 25, 2019 Content info: 64 Pages
Description

Summary:

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Prostaglandin E2 Receptor EP4 Subtype - Pipeline Review, H2 2019, outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 1, 6 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology, Women's Health, Musculoskeletal Disorders and Respiratory which include indications Breast Cancer, Endometriosis, Gastric Cancer, Inflammatory Pain, Liver Cancer, Lung Cancer, Pain, Prostate Cancer, Allergies, Arthritis Pain, Autoimmune Disorders, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Colorectal Cancer, Esophageal Cancer, Familial Adenomatous Polyposis, Gastrointestinal Tract Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Inflammatory Bowel Disease, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Post-Operative Pain, Rectal Cancer, Rheumatoid Arthritis, Solid Tumor, Triple-Negative Breast Cancer (TNBC) and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
  • The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC1970TDB

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Overview
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development
    • ARTham Therapeutics Inc
    • AskAt Inc
    • Eisai Co Ltd
    • Eli Lilly and Co
    • GlaxoSmithKline Plc
    • Kaken Pharmaceutical Co Ltd
    • Mesentech Inc
    • NB Health Laboratory Co Ltd
    • Ono Pharmaceutical Co Ltd
    • RaQualia Pharma Inc
    • Rottapharm Biotech Srl
    • Shanghai Haishi Biopharmaceutical Co Ltd
    • Sosei Heptares
    • Tempest Therapeutics Inc
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles
    • AAT-008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARTEP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CR-6086 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-7046 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • grapiprant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-726701A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KAG-308 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-4578 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RMX-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize EP4 Receptor for Osteoporosis and Osteogenesis Imperfecta - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize EP4 Receptor for Inflammatory Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target Prostanoid EP4 Receptor for Inflammatory Bowel Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TPST-1495 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Products
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 (an Oral EP4 Antagonist) for locally advanced rectal cancer at ESMO 2019
      • May 07, 2019: Kyn Therapeutics strengthens leadership team with key appointments
      • Dec 20, 2018: Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007
      • Jul 19, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China
      • Apr 17, 2018: Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist
      • Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China
      • Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China
      • Dec 18, 2017: Investigational new drug application for EP4 antagonist AAT-007 was approved by the National Food and Drug Administration of the People's Republic of China
      • Sep 01, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Korea
      • Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress
      • Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at the ESMO 2017 Congress
      • Jun 30, 2017: India Patent Office Granted AskAt a Substance Patent of EP4 antagonist(AAT-007)
      • Apr 25, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Japan
      • Mar 30, 2017: Treatment of Cancer Use Patent for EP4 antagonist Approved in US
      • Aug 17, 2016: Treatment of Cancer Use Patent for EP4 antagonist Approved in China
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by ARTham Therapeutics Inc, H2 2019
  • Pipeline by AskAt Inc, H2 2019
  • Pipeline by Eisai Co Ltd, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by GlaxoSmithKline Plc, H2 2019
  • Pipeline by Kaken Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Mesentech Inc, H2 2019
  • Pipeline by NB Health Laboratory Co Ltd, H2 2019
  • Pipeline by Ono Pharmaceutical Co Ltd, H2 2019
  • Pipeline by RaQualia Pharma Inc, H2 2019
  • Pipeline by Rottapharm Biotech Srl, H2 2019
  • Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, H2 2019
  • Pipeline by Sosei Heptares, H2 2019
  • Pipeline by Tempest Therapeutics Inc, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019
  • Discontinued Products, H2 2019 (Contd..1), H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top